Evidence map›Paper›PMID 33519427›Full record

ArticleFrontiers in pharmacology2020

Sex-Associated Differences in Cytomegalovirus Prevention: Prophylactic Strategy is Potentially Associated With a Strong Kidney Function Impairment in Female Renal Transplant Patients.

Arturo Blazquez-Navarro, Chantip Dang-Heine, Chris Bauer, Nicole Wittenbrink, Kerstin Wolk, Robert Sabat, Oliver Witzke, Timm H Westhoff, Birgit Sawitzki, Petra Reinke and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Arturo Blazquez-NavarroDepartment of Biology, Systems Immunology Lab, Humboldt-Universität zu Berlin, Berlin, Germany.
Chantip Dang-HeineBerlin Institute of Health Center for Regenerative Therapies (BCRT), Berlin-Brandenburger Centrum für Regenerative Therapien, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Chris BauerMicroDiscovery GmbH, Berlin, Germany.
Nicole WittenbrinkDepartment of Biology, Systems Immunology Lab, Humboldt-Universität zu Berlin, Berlin, Germany.
Kerstin WolkBerlin Institute of Health Center for Regenerative Therapies (BCRT), Berlin-Brandenburger Centrum für Regenerative Therapien, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Robert SabatDepartment of Dermatology and Allergy, Psoriasis Research and Treatment Center, Institute of Medical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Oliver WitzkeKlinik für Infektiologie, Universitätsklinikum Essen, Essen, Germany.
Timm H WesthoffCenter for Translational Medicine, Universitätsklinikum der Ruhr-Universität Bochum, Herne, Germany.
Birgit SawitzkiBerlin Institute of Health Center for Regenerative Therapies (BCRT), Berlin-Brandenburger Centrum für Regenerative Therapien, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Petra ReinkeBerlin Institute of Health Center for Regenerative Therapies (BCRT), Berlin-Brandenburger Centrum für Regenerative Therapien, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Oliver ThomuschKlinik für Allgemein- und Viszeralchirurgie, Universitätsklinikum Freiburg, Freiburg, Germany.
Christian HugoMedizinische Klinik III - Bereich Nephrologie, Universitätsklinikum Carl Gustav Carus, Dresden, Germany.
Nina BabelBerlin Institute of Health Center for Regenerative Therapies (BCRT), Berlin-Brandenburger Centrum für Regenerative Therapien, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Michal Or-GuilDepartment of Biology, Systems Immunology Lab, Humboldt-Universität zu Berlin, Berlin, Germany.
Berlin-Brandenburger Centrum für Regenerative Therapien · DECharité - Universitätsmedizin Berlin · DEHumboldt-Universität zu Berlin · DEUniversity Hospitals of the Ruhr-University of Bochum · DEEssen University Hospital · DEMicroDiscovery (Germany) · DEUniversity Hospital Carl Gustav Carus · DEUniversity Medical Center Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-transplantation cytomegalovirus (CMV) syndrome can be prevented using the antiviral drug (val)ganciclovir. (Val)ganciclovir is typically administered following a prophylactic or a pre-emptive strategy. The prophylactic strategy entails early universal administration, the pre-emptive strategy, early treatment in case of infection. However, it is not clear which strategy is superior with respect to transplantation outcome; sex-specific effects of these prevention strategies are not known. We have retrospectively analyzed 540 patients from the multi-centre Harmony study along eight pre-defined visits: 308 were treated according to a prophylactic, 232 according to a pre-emptive strategy. As expected, we observed an association of prophylactic strategy with lower incidence of CMV syndrome, delayed onset and lower viral loads compared to the pre-emptive strategy. However, in female patients, the prophylactic strategy was associated with a strong impairment of glomerular filtration rate one year post-transplant (difference: -11.8 ± 4.3 ml min

Indexed as

cytomegalovirusgendergraft functionpreventionvalganciclovir

Identifiers

PMID33519427
PMCPMC7845412
OpenAlexW3125659758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.